Instadose Pharma (Instadose Pharma) Total Current Assets : $0.07 Mil (As of Feb. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Instadose Pharma Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Instadose Pharma's total current assets for the quarter that ended in Feb. 2022 was $0.07 Mil.

Instadose Pharma Total Current Assets Historical Data

The historical data trend for Instadose Pharma's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Instadose Pharma Total Current Assets Chart

Instadose Pharma Annual Data

Trend

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Total Current Assets

Get a 7-Day Free Trial

Instadose Pharma Quarterly Data
	May17	Aug17	Nov17	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22
Total Current Assets	Get a 7-Day Free Trial															-	-	-	-	0.07

Instadose Pharma Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Instadose Pharma's Total Current Assets for the fiscal year that ended in Nov. 2021 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0	+	0	+	0	+	0
	=	0.00

Instadose Pharma's Total Current Assets for the quarter that ended in Feb. 2022 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.004	+	0	+	0	+	0.066
	=	0.07

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Instadose Pharma (OTCPK:INSD) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Instadose Pharma's Liquidation Value for the quarter that ended in Feb. 2022 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.004	-	8.089	+	0.75 * 0	+	0.5 * 0
=	-8.09

Instadose Pharma Total Current Assets Related Terms

Thank you for viewing the detailed overview of Instadose Pharma's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Instadose Pharma (Instadose Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Instadose Pharma Corp (OTCPK:INSD) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

5500 North Service Road, Suite 301, Burlington, ON, CAN, L7L 6W6

Website

https://www.instadosepharma.com

Instadose Pharma Corp, formerly Mikrocoze Inc is seeking to create a global distribution platform for medicinal cannabis and cannabinoid oil. The company endeavors to utilize the Global Distribution Platform to open the commercial gateway to a new wholesale marketplace along with providing pharmaceutical industry companies with large, sustainable, consistent, diverse, and low?cost supplies of high?quality medicinal cannabis and cannabinoid oil for use in bulk as an active pharmaceutical ingredient.